. 2020 Nov 11;11:602057. doi: 10.3389/fmicb.2020.602057

TABLE 3.

Antibiofilm effects of simultaneous (MBEC_SIM) or staggered (MBEC_STA) phage–antibiotic combinations against clinical strains.

Antibiotic	VAN		DAP		FOF		GEN
MRSA strains	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA
MRSA1	>256 (NS)^a	>256 (NS)^a	8 (0.125, S)	8 (0.125, S)	>256 (NS)^a	64 (0.06, S)^b	64 (0.25, S)	64 (0.25, S)
MRSA2	>256 (NS)^a	>256 (NS)^a	16 (0.125, S)	16 (0.125, S)	>256 (NS)^a	256 (0.25, S)^b	256 (0.5, NS)	64 (0.125, S)
MRSA3	>256 (NS)^a	>256 (NS)^a	16 (0.25, S)	16 (0.25, S)	>256 (NS)^a	>256 (NS)^a	128 (0.25, S)	64 (0.125, S)
MRSA4	>256 (NS)^a	>256 (NS)^a	16 (0.125, S)	16 (0.125, S)	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a

Antibiotic	FLU		CFZ		FOF		GEN
MSSA strains	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA	MBEC_SIM	MBEC_STA

MSSA1	128 (0.125, S)	64 (0.006, S)	>256 (NS)^a	256 (0.25, S)^b	>256 (NS)^a	>256 (NS)^a	128 (0.25, S)	128 (0.25, S)
MSSA2	256 (0.25, S)	32 (0.003, S)	>256 (NS)^a	128 (0.125, S)^b	>256 (NS)^a	64 (0.006, S)^b	128 (0.25, S)	128 (0.25, S)
MSSA3	256 (0.25, S)	32 (0.003, S)	>256 (NS)^a	256 (0.25, S)^b	>256 (NS)^a	256 (0.25, S)^b	>256 (NS)^a	>256 (NS)^a
MSSA4	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	256 (0.25, S)^b	>256 (NS)^a	>256 (NS)^a
MSSA5	256 (0.5, NS)	256 (0.5, NS)	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a	>256 (NS)^a
MSSA6	>256 (NS)^a	32 (0.003, S)^b	>256 (NS)^a	16 (0.015, S)^b	>256 (NS)^a	32 (0.003, S)^b	256 (0.25, S)	256 (0.25, S)

MBEC concentration values are expressed in μg/ml. In brackets is shown the ratio value followed by the ratio interpretation. VAN, vancomycin; FLU, flucloxacillin; DAP, daptomycin; CFZ, cefazolin; FOF, fosfomycin; GEN, gentamicin; S, synergism; NS, no synergism. ^aMBEC value above 1/4xMBEC_alone (considering MBEC_alone equal to 1,024 μg/ml), thus MBEC_phage/MBEC_alone ratio is interpreted as >0.25 (NS). ^bMBEC_alone considered equal to 1,024 μg/ml for MBEC_phage/MBEC_alone ratio calculations.